NASDAQ:SUPNSupernus Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Supernus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.29 +1.03 (+4.63 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$22.33Now: $23.29▼$23.4450-Day Range$22.30MA: $23.63▼$24.9452-Week Range$13.12Now: $23.29▼$33.43Volume463,958 shsAverage Volume561,581 shsMarket Capitalization$1.22 billionP/E Ratio10.73Dividend YieldN/ABeta1.55 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.25, Supernus Pharmaceuticals has a potential upside of 38.5% from its current price of $23.28.Amount of Analyst CoverageSupernus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesSupernus Pharmaceuticals has received 442 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSupernus Pharmaceuticals has received 281 “underperform” votes. (Add your “underperform” vote.)Community SentimentSupernus Pharmaceuticals has received 61.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote “Outperform” if you believe SUPN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSupernus Pharmaceuticals does not currently pay a dividend.Dividend GrowthSupernus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Supernus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $745,035.00 in company stock.Percentage Held by InsidersOnly 7.86% of the stock of Supernus Pharmaceuticals is held by insiders.Percentage Held by Institutions92.73% of the stock of Supernus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Supernus Pharmaceuticals are expected to grow by 22.15% in the coming year, from $1.49 to $1.82 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Supernus Pharmaceuticals is 10.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.52.Price to Earnings Ratio vs. SectorThe P/E ratio of Supernus Pharmaceuticals is 10.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.79.Price to Book Value per Share RatioSupernus Pharmaceuticals has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.97 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:SUPN Previous Symbol CUSIP86845910 CIK1356576 Webwww.supernus.com Phone301-838-2500Debt Debt-to-Equity Ratio0.62 Current Ratio3.31 Quick Ratio3.16Price-To-Earnings Trailing P/E Ratio10.73 Forward P/E Ratio15.63 P/E GrowthN/A Sales & Book Value Annual Sales$392.76 million Price / Sales3.12 Cash Flow$2.61 per share Price / Cash Flow8.91 Book Value$11.35 per share Price / Book2.05Profitability EPS (Most Recent Fiscal Year)$2.10 Net Income$113.06 million Net Margins28.90% Return on Equity20.31% Return on Assets10.28%Miscellaneous Employees448 Outstanding Shares52,539,000Market Cap$1.22 billion Next Earnings Date8/4/2020 (Estimated) OptionableOptionable $23.29 +1.03 (+4.63 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SUPN News and Ratings via Email Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions How has Supernus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SUPN shares have increased by 44.2% and is now trading at $23.29. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Supernus Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Supernus Pharmaceuticals. When is Supernus Pharmaceuticals' next earnings date? Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Supernus Pharmaceuticals. How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals Inc (NASDAQ:SUPN) posted its quarterly earnings data on Tuesday, May, 5th. The specialty pharmaceutical company reported $0.40 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.30 by $0.10. The specialty pharmaceutical company had revenue of $94.98 million for the quarter, compared to analysts' expectations of $84.01 million. Supernus Pharmaceuticals had a return on equity of 20.31% and a net margin of 28.90%. The business's revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.34 earnings per share. View Supernus Pharmaceuticals' earnings history. What price target have analysts set for SUPN? 6 equities research analysts have issued 12-month price objectives for Supernus Pharmaceuticals' stock. Their forecasts range from $24.00 to $50.00. On average, they anticipate Supernus Pharmaceuticals' share price to reach $32.25 in the next year. This suggests a possible upside of 38.5% from the stock's current price. View analysts' price targets for Supernus Pharmaceuticals. Has Supernus Pharmaceuticals been receiving favorable news coverage? Press coverage about SUPN stock has trended somewhat positive on Monday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Supernus Pharmaceuticals earned a daily sentiment score of 1.6 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Supernus Pharmaceuticals. Who are some of Supernus Pharmaceuticals' key competitors? Some companies that are related to Supernus Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), Pfizer (PFE), Exelixis (EXEL), Netflix (NFLX), Cara Therapeutics (CARA) and Corcept Therapeutics (CORT). Who are Supernus Pharmaceuticals' key executives? Supernus Pharmaceuticals' management team includes the following people: Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 58)Mr. Gregory S. Patrick, Sr. VP & CFO (Age 68)Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 62)Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 67)Dr. Todd Horich M.B.A., Ph.D., VP of Marketing What is Supernus Pharmaceuticals' stock symbol? Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN." Who are Supernus Pharmaceuticals' major shareholders? Supernus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.44%), Bridge City Capital LLC (0.24%), Ingalls & Snyder LLC (0.14%), First Trust Advisors LP (0.11%), Comerica Bank (0.11%) and SG Americas Securities LLC (0.10%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick and Jack A Khattar. View institutional ownership trends for Supernus Pharmaceuticals. Which institutional investors are selling Supernus Pharmaceuticals stock? SUPN stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Mackay Shields LLC, Pacer Advisors Inc., Scout Investments Inc., and Envestnet Asset Management Inc.. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Frederick M Hudson, and Gregory S Patrick. View insider buying and selling activity for Supernus Pharmaceuticals. Which institutional investors are buying Supernus Pharmaceuticals stock? SUPN stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, SG Americas Securities LLC, Nisa Investment Advisors LLC, Wakefield Asset Management LLLP, Exchange Traded Concepts LLC, BBVA USA Bancshares Inc., Campbell & CO Investment Adviser LLC, and Comerica Bank. View insider buying and selling activity for Supernus Pharmaceuticals. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Supernus Pharmaceuticals' stock price today? One share of SUPN stock can currently be purchased for approximately $23.29. How big of a company is Supernus Pharmaceuticals? Supernus Pharmaceuticals has a market capitalization of $1.22 billion and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe. What is Supernus Pharmaceuticals' official website? The official website for Supernus Pharmaceuticals is www.supernus.com. How can I contact Supernus Pharmaceuticals? Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected] This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
